P
PRME icon

&Partners’s Prime Medicine PRME Stock Holding History

&Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Sell
57,460
-2,010
-3% -$6.67K ﹤0.01% 2353
2026
Q1 		$207K Sell
59,470
-882
-1% -$3.36K ﹤0.01% 2232
2025
Q4 		$209K Buy
60,352
+48,504
+409% +$216K ﹤0.01% 2123
2025
Q3 		$70.6K Buy
+11,848
New +$48.1K ﹤0.01% 2069

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

&Partners's PRME Position: Q2 2026 in Review

&Partners reduced its Prime Medicine (PRME) stake by 3.4% in Q2 2026, selling an estimated $6.67K and leaving 57,460 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

&Partners first reported a position in PRME in Q3 2025 and has held it in 4 quarters since. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • &Partners held 57,460 shares of Prime Medicine worth $211K as of Q2 2026.
  • &Partners sold 2,010 Prime Medicine shares in Q2 2026, an estimated $6.67K.
  • Prime Medicine made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2353 holding.
  • &Partners first reported a position in Prime Medicine in Q3 2025 and has held it in 4 quarters since.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.